APC^CDH1 Targets MgcRacGAP for Destruction in the Late M Phase

• Koutarou Nishimura,

  Affiliation Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan

  ⨯
• Toshihiko Oki,

  Affiliations Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan, Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan

  ⨯
• Jiro Kitaura,

  Affiliation Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan

  ⨯
• Shinji Kuninaka,

  Affiliations Division of Gene Regulation, Institute for Advanced Medical Research, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan, CREST, Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan

  ⨯
• Hideyuki Saya,

  Affiliation Division of Gene Regulation, Institute for Advanced Medical Research, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan

  ⨯
• Asako Sakaue-Sawano,

  Affiliations Laboratory for Cell Function and Dynamics, Advanced Technology Development Group, Brain Science Institute, RIKEN, Wako-city, Saitama, Japan, Life Function and Dynamics, ERATO, JST, Wako-city, Saitama, Japan

  ⨯
• Atsushi Miyawaki,

  Affiliations Laboratory for Cell Function and Dynamics, Advanced Technology Development Group, Brain Science Institute, RIKEN, Wako-city, Saitama, Japan, Life Function and Dynamics, ERATO, JST, Wako-city, Saitama, Japan

  ⨯
• Toshio Kitamura

  * E-mail: kitamura@ims.u-tokyo.ac.jp

  Affiliations Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan, Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan

  ⨯